课题基金 / 基金详情

Evaluation of potential biomarkers of successful treatment of latent tuberculosis

Evaluation of potential biomarkers of successful treatment of latent tuberculosis
成功治疗潜伏性结核病的潜在生物标志物评估
批准号：
223992
负责人：
Menzies Richard
金额：
$38.29万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-03-01 至 2014-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=223992&lang=en
关键词：
Biomarkers Latent Tuberculosis Treatment Of Tuberculosis Tuberculosis Tuberculosis Prevention

项目摘要

项目成果

Menzies Richard的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Tuberculosis (TB) infects about a third of the world's population and is the most important infectious cause of death in adults' worldwide. A cornerstone of TB control is treating TB while it is still dormant or latent, before it causes illness. The curre
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair - Tier 1
  • 批准号：
    415507
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2019
  • 负责人：
    Menzies Richard
  • 依托单位：
    McGill University
Religious communities to end TB (ReCET)
  • 批准号：
    372880
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $1.42万
  • 财政年份：
    2017
  • 负责人：
    Menzies Richard
  • 依托单位：
    Stellenbosch University (South Africa)
Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease.
A randomized trial to compare effectiveness of 4 months Rifampin (4 RIF) with 9 months Isoniazid (9 INH) in the prevention of active TB in children: The P4v9 Trial
海外基金